AdAlta Company Description

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia.

Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration.

AdAlta Limited has collaborative partnerships with GE Healthcare Technologies Inc to develop i-body enabled PET imaging agents for use in immuno-oncology; and Carina Biotech Pty Ltd to develop CAR-T cell therapies for solid tumor.

The company was incorporated in 2006 and is based in Camberwell, Australia.

AdAlta Limited

Country	Australia
Founded	2006
Industry	Biotechnology
Sector	Healthcare
Employees	9
CEO	Timothy Oldham

Contact Details

Address: Suite 201 Camberwell, 3124 Australia
Phone	61 3 9479 5159
Website	adalta.com.au

Stock Details

Ticker Symbol	1AD
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU0000001AD2
SIC Code	2836

Key Executives

Name	Position
Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D.	Chief Executive Officer, MD and Director
Angus Tester Ph.D.	Senior Director of Operations
Janette Dixon	Head of Business Development
Cameron Peter Jones C.A.	Company Secretary